Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBRACE: Emapalumab in IFNγ-driven Sepsis
NCT06694701Phase 2Active, not recruiting
- Sponsor
- Hellenic Institute for the Study of Sepsis
- Start
- Mar 2025
- Primary completion
- Nov 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of emapalumab in sepsis, sponsored by Hellenic Institute for the Study of Sepsis. Started Mar 2025; status: active, not recruiting.
02
Drugs
emapalumab
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT06694701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06694701.